Literature DB >> 1602745

Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function.

R Kisilevsky1, L Subrahmanyan.   

Abstract

The affinity of high density lipoproteins (HDL), or HDL carrying serum amyloid A (HDL/SAA), for hepatocytes or peritoneal macrophages was examined, as part of an investigation exploring the principal function of SAA and how this may be related to amyloidogenesis. The binding results in conjunction with SAA's existence primarily on HDL during inflammation, and HDL's known "reverse cholesterol transport" function suggest a clear role for SAA in the afferent arm of the reverse cholesterol transport pathway during the process of inflammation. The presence of SAA reduced HDL's affinity for normal hepatocytes by a factor of 2. In contrast, HDL/SAA had a 3- to 4-fold higher affinity for macrophages than HDL alone. Furthermore, the number of binding sites for HDL/SAA increased on macrophages during inflammation, while decreasing on hepatocytes. The net effect was a significant shift in HDL cholesterol carrying capacity towards the macrophage. Competition experiments demonstrated that HDL/SAA is only half as effective as HDL in inhibiting radiolabeled HDL binding to macrophages. This is in keeping with the reduced apolipoprotein A-1 content in HDL/SAA. Strikingly, although HDL contains twice as much apolipoprotein A-1 as HDL/SAA, it is only one-tenth as effective as HDL/SAA in inhibiting radiolabeled HDL/SAA binding to macrophages. The latter results suggest that there is a specific SAA binding site on macrophages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602745

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  43 in total

1.  A novel cis-acting element is essential for cytokine-mediated transcriptional induction of the serum amyloid A gene in nonhepatic cells.

Authors:  A Ray; B K Ray
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 2.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

3.  Automated measurement of a constitutive isotype of serum amyloid A/SAA4 and comparison with other apolipoproteins.

Authors:  T Yamada; A Wada; T Yamaguchi; Y Itoh; T Kawai
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  [Lipoproteins and diabetic nephropathy].

Authors:  T Bertsch; J Aufenanger
Journal:  Med Klin (Munich)       Date:  1998-01-15

5.  SAA: a link between cholesterol efflux capacity and inflammation?

Authors:  Michael J Thomas; Mary G Sorci-Thomas
Journal:  J Lipid Res       Date:  2015-06-15       Impact factor: 5.922

Review 6.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

7.  Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease.

Authors:  Brad P Dieter; Sterling M McPherson; Maryam Afkarian; Ian H de Boer; Rajnish Mehrotra; Robert Short; Celestina Barbosa-Leiker; Radica Z Alicic; Rick L Meek; Katherine R Tuttle
Journal:  J Diabetes Complications       Date:  2016-07-27       Impact factor: 2.852

8.  Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2.

Authors:  W Pruzanski; F C de Beer; M C de Beer; E Stefanski; P Vadas
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

9.  Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice.

Authors:  Jonathan S Wall; Tina Richey; Amy Allen; Robert Donnell; Steve J Kennel; Alan Solomon
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

10.  Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters.

Authors:  I Hardardóttir; A H Moser; J Fuller; C Fielding; K Feingold; C Grünfeld
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.